For the first time, the NHS in England and Wales will offer an injection to prevent HIV, aligning with Scotland's policy. This long-acting shot could be a breakthrough in HIV prevention, aiming to end new cases by 2030!
A groundbreaking injectable HIV prevention drug will be available for just $40 a year in over 100 countries by 2027, thanks to agreements between Unitaid, the Gates Foundation, and Indian pharmaceutical companies.
A groundbreaking partnership aims to provide low-cost lenacapavir to millions at risk of HIV in low- and middle-income countries, potentially transforming HIV prevention efforts worldwide.
The EU has recommended lenacapavir, an injectable drug for HIV prevention, which could drastically reduce transmission rates. With nearly 100% effectiveness, it promises a new era in combating HIV.
The European Medicines Agency has recommended the approval of lenacapavir, a twice-yearly injectable drug that could revolutionize HIV prevention and significantly reduce transmission rates globally.
The WHO's endorsement of lenacapavir, a twice-yearly injectable drug, could transform HIV prevention for high-risk groups, especially amid funding concerns. This breakthrough may help millions and push us closer to an AIDS-free world.
Recent U.S. funding cuts to AIDS programs have sparked alarms, with UNAIDS warning of potential catastrophic rises in HIV infections and AIDS-related deaths. The future of global health hangs in the balance.
A new Covid variant, NB.1.8.1, raises alarms for its potential to spread rapidly and evade antibodies. Meanwhile, the FDA approves a long-lasting HIV injection, and concerns about public safety arise with ICE's rule changes.
In a crucial turn of events, the Trump administration has lifted its freeze on nearly $20 million for HIV prevention programs following significant public outcry. This funding is vital for combating new infections and supporting the LGBTQ+ community.
In a landmark ruling, the U.S. Supreme Court ensures that health insurers must continue to cover preventive services like cancer screenings and HIV medications at no cost to patients. This decision safeguards vital health benefits amidst ongoing challenges to Obamacare.
